Fenfluramine HCl (Fintepla®) provides long‐term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open‐label extension study

• Published in: Epilepsia (Copenhagen) Vol. 61; no. 11; pp. 2396 - 2404
• Main Authors: Sullivan, Joseph, Scheffer, Ingrid E., Lagae, Lieven, Nabbout, Rima, Pringsheim, Milka, Talwar, Dinesh, Polster, Tilman, Galer, Bradley, Lock, Michael, Agarwal, Anupam, Gammaitoni, Arnold, Morrison, Glenn, Farfel, Gail
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.11.2020; John Wiley and Sons Inc
• Subjects: Adolescent; Appetite loss; Child; Child, Preschool; Clinical trials; Convulsions & seizures; Coronary artery disease; Double-Blind Method; Dravet syndrome; Echocardiography; Epilepsies, Myoclonic - diagnosis; Epilepsies, Myoclonic - drug therapy; Epilepsies, Myoclonic - epidemiology; epilepsy; Female; Fenfluramine; Fenfluramine - administration & dosage; Fenfluramine - adverse effects; Fever; Fever - chemically induced; Full‐length Original Research; Heart diseases; Humans; Longitudinal Studies; Lung diseases; Male; Patients; Rhinopharyngitis; Seizures; Seizures - diagnosis; Seizures - drug therapy; Seizures - epidemiology; Serotonin Uptake Inhibitors - administration & dosage; Serotonin Uptake Inhibitors - adverse effects; Statistical analysis; Stiripentol; Treatment Outcome; Young Adult; epilepsy; fenfluramine; Dravet syndrome

Objective Fenfluramine has been shown to provide clinically meaningful and statistically significant reductions in convulsive seizure frequency in children and adolescents (aged 2‐18 years) with Dravet syndrome in two randomized, placebo‐controlled clinical trials. The objective of this analysis was...